Radiobiological effect based treatment plan optimization with the linear quadratic model;Radiobiologische effektbasierte optimierung von therapieplänen mit dem linear-quadratischen modell

Zeitschrift fur Medizinische Physik

Volumn 20, Issue 3, 2010, Pages 188-196

  Schell, Stefan ^a   Wilkens, Jan J ^a   Oelfke, Uwe ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Biological optimization; Fractionation; Linear quadratic model

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HISTOGRAM; HUMAN; MALE; PREDICTION; PROSTATE CANCER; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RADIATION INJURY; RADIATION RESPONSE; RADIOBIOLOGY; STATISTICAL MODEL; TISSUE SPECIFICITY; TREATMENT PLANNING;

DOSE FRACTIONATION; HEAD AND NECK NEOPLASMS; HUMANS; LINEAR MODELS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 77956617813     PISSN: 09393889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.zemedi.2010.02.003     Document Type: Article

References (25)

1. Niemierko A. Biological optimization. In: Bortfeld T, Schmidt-Ullrich R, DeNeve W, Wazer DE, editors. Image-Guided IMRT. Springer; 2006. p. 199-216.
2. Alber M. Normal tissue dose-effect models in biological dose optimisation. Z Med Phys 2008, 18(2):102-110.
3. Hoffmann A.L., den Hertog D., Siem A.Y.D., Kaanders J.H.A.M., Huizenga H. Convex reformulation of biologically-based multi-criteria intensity-modulated radiation therapy optimization including fractionation effects. Phys Med Biol 2008, 53(22):6345-6362.
4. Altman M.B., Chmura S.J., Deasy J.O., Roeske J.C. Optimization of the temporal pattern of radiation: an IMRT based study. Int J Radiat Oncol Biol Phys 2006, 66(3):898-905.
5. Bortfeld T., Paganetti H. The biologic relevance of daily dose variations in adaptive treatment planning. Int J Radiat Oncol Biol Phys 2006, 65(3):899-906.
6. Brenner D.J. The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin Radiat Oncol 2008, 18(4):234-239.
7. Lea D.E., Catcheside D.G. The mechanism of the induction by radiation of chromosome aberrations in tradescantia. J Genet 1942, 44:216-245.
8. Wang J.Z., Li X.A., D'Souza W.D., Stewart R.D. Impact of prolonged fraction delivery times on tumor control: a note of caution for intensity-modulated radiation therapy (IMRT). Int J Radiat Oncol Biol Phys 2003, 57(2):543-552.
9. Oelfke U., Bortfeld T. Inverse planning for photon and proton beams. Med Dosim 2001, 26(2):113-124.
10. Wilkens J.J., Oelfke U. Optimization of radiobiological effects in intensity modulated proton therapy. Med Phys 2005, 32(2):455-465.
11. Zhu C., Byrd R.H., Lu P., Nocedal J. Algorithm 778: L-BFGS-B: fortran subroutines for large-scale bound-constrained optimization. ACM T Math Software 1997, 23(4):550-560.
12. Pflugfelder D., Wilkens J.J., Nill S., Oelfke U. A comparison of three optimization algorithms for intensity modulated radiation therapy. Z Med Phys 2008, 18(2):111-119.
13. Joiner M.C., Marples B., Lambin P., Short S.C., Turesson I. Low-dose hypersensitivity: current status and possible mechanisms. Int J Radiat Oncol Biol Phys 2001, 49(2):379-389.
14. Jani A.B., Hand C.M., Pelizzari C.A., Roeske J.C., Krauz L., Vijayakumar S. Biological-effective versus conventional dose volume histograms correlated with late genitourinary and gastrointestinal toxicity after external beam radiotherapy for prostate cancer: a matched pair analysis. BMC Cancer 2003, 3:16.
15. Fowler J.F. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 2005, 44(3):265-276.
16. Yang Y., Xing L. Optimization of radiotherapy dose-time fractionation with consideration of tumor specific biology. Med Phys 2005, 32(12):3666-3677.
17. Webb S., Nahum A.E. A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density. Phys Med Biol 1993, 38(6):653-666.
18. Kim Y., Tomé W.A. Risk-adaptive optimization: Selective boosting of high-risk tumor subvolumes. Int J Radiat Oncol Biol Phys 2006, 66(5):1528-1542.
19. Alber M., Paulsen F., Eschmann S.M., Machulla H.J. On biologically conformal boost dose optimization. Phys Med Biol 2003, 48(2):N31-N35.
20. Fowler J.F., Ritter M.A., Chappell R.J., Brenner D.J. What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol Biol Phys 2003, 56(4):1093-1104.
21. Miles E.F., Lee W.R. Hypofractionation for prostate cancer: a critical review. Semin Radiat Oncol 2008, 18(1):41-47.
22. Bentzen S.M., Ritter M.A. The α-β-ratio for prostate cancer: what is it, really?. Radiother Oncol 2005, 76(1):1-3.
23. Leborgne F., Fowler J.F. Acute toxicity after hypofractionated conformal radiotherapy for localized prostate cancer: Nonrandomized contemporary comparison with standard fractionation. Int J Radiat Oncol Biol Phys 2008, 72(3):770-776.
24. Brenner D.J., Hlatky L.R., Hahnfeldt P.J., Hall E.J., Sachs R.K. A convenient extension of the linear-quadratic model to include redistribution and reoxygenation. Int J Radiat Oncol Biol Phys 1995, 32(2):379-390.
25. Lian J., Xing L. Incorporating model parameter uncertainty into inverse treatment planning. Med Phys 2004, 31(9):2711-2720.